Message from the Chairman and Founder
OrganTech, Inc. was established in 2008 with the mission of “contributing to the maintenance of global health and the improvement of quality of life (QOL) through the creation of 21st-century medicine.”
Over the course of ten years until 2001, I worked at two pharmaceutical companies, where I came to understand both the value and the challenges of drug discovery using small and macromolecular compounds. Aspiring to create an innovative medical system and a high value-added industry suitable for the 21st century, I began my research activities as a Principal Investigator at Tokyo University of Science. My goal was regenerative medicine driven by developmental biology and the body’s self-healing capacity—an innovation in three-dimensional organ regeneration, where transplantation had remained the only available medical technology. Fortunate to work with outstanding students, in 2007 we developed the Organ Germ Method, the world’s first foundational technology for regenerating organ germs through three-dimensional cell manipulation. Based on this achievement, I founded a venture company together with supporters to advance the commercialization of organ regenerative medicine as 21st-century medicine.
During the first decade, we created intellectual property through world-first innovations, positioning the company as a patent-holding enterprise while promoting research and development within academia. Using the Organ Germ Method as our core platform, we went on to demonstrate the functional regeneration of teeth, hair follicles, salivary glands, and lacrimal glands in vivo, opening new frontiers in organ regeneration research while building a robust intellectual property portfolio. Later, I transferred my research base to the RIKEN Center for Biosystems Dynamics Research, where we initiated business development. Through the promotion of academia–industry collaborations with private companies, we completed much of the pipeline that underpins today’s OrganTech. At one point, due to the major social disruptions caused by the COVID-19 pandemic, I made the difficult decision to suspend the company’s business operations. However, in 2023, thanks to the encouragement of new supporters, OrganTech, Inc. was relaunched under a renewed structure. I regard this as the result of invaluable support from shareholders, students, researchers, and corporate collaborators, as well as a response to pressing social needs.
Today, within our 2050 Vision, OrganTech is advancing research and development with a focus on three core pipelines: Next-Generation Biohybrid Implants, Hair Regeneration, and Three-Dimensional Artificial Skin. The development of next-generation biohybrid implants, derived from our tooth regeneration research, has already progressed to the clinical stage. Our hair regeneration program has expanded into four distinct pipelines through sustained basic research. Our three-dimensional artificial skin technology has entered into licensing agreements and grown into a commercial business. Furthermore, drawing on our accumulated achievements, we are also supporting corporate R&D initiatives.
As an original “research and development-driven company” based on new concepts, OrganTech aims to contribute to the realization of a healthier and longer-lived global society by sustainably expanding into fields such as preventive medicine, wellness, QOL medicine, and life-regenerative medicine. Our entire team is united in working toward this vision. We sincerely ask for your continued understanding, support, and guidance.
September 23, 2025
Takashi Tsuji, Ph.D.
Chairman & Founder
OrganTech, Inc.
